The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

The Danish anti-obesity drugmaker slashed prices for its Wegovy and Ozempic treatments. Shares fell more than 1%. ↘️ [XPeng ...

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.